Pharmacological blockade of the vanilloid receptor TRPV1 elicits marked hyperthermia in humans

&NA; The vanilloid receptor TRPV1 has been identified as a molecular target for the treatment of pain associated with inflammatory diseases and cancer. Hence, TRPV1 antagonists have been considered for therapeutic evaluation in such diseases. During Phase I clinical trials with AMG 517, a highly selective TRPV1 antagonist, we found that TRPV1 blockade elicited marked, but reversible, and generally plasma concentration‐dependent hyperthermia. Similar to what was observed in rats, dogs, and monkeys, hyperthermia was attenuated after repeated dosing of AMG 517 (at the highest dose tested) in humans during a second Phase I trial. However, AMG 517 administered after molar extraction (a surgical cause of acute pain) elicited long‐lasting hyperthermia with maximal body temperature surpassing 40 °C, suggesting that TRPV1 blockade elicits undesirable hyperthermia in susceptible individuals. Mechanisms of AMG 517‐induced hyperthermia were then studied in rats. AMG 517 caused hyperthermia by inducing tail skin vasoconstriction and increasing thermogenesis, which suggests that TRPV1 regulates vasomotor tone and metabolic heat production. In conclusion, these results demonstrate that: (a) TRPV1‐selective antagonists like AMG 517 cannot be developed for systemic use as stand alone agents for treatment of pain and other diseases, (b) individual susceptibility influences magnitude of hyperthermia observed after TRPV1 blockade, and (c) TRPV1 plays a pivotal role as a molecular regulator for body temperature in humans.

[1]  N. Gavva,et al.  The TRPV1 receptor and nociception. , 2006, Seminars in cell & developmental biology.

[2]  A. A. Romanovsky,et al.  Selected contribution: ambient temperature for experiments in rats: a new method for determining the zone of thermal neutrality. , 2002, Journal of applied physiology.

[3]  Mark H. Norman,et al.  AMG 9810 [(E)-3-(4-t-Butylphenyl)-N-(2,3-dihydrobenzo[b][1,4] dioxin-6-yl)acrylamide], a Novel Vanilloid Receptor 1 (TRPV1) Antagonist with Antihyperalgesic Properties , 2005, Journal of Pharmacology and Experimental Therapeutics.

[4]  A. A. Romanovsky,et al.  Nonthermal Activation of Transient Receptor Potential Vanilloid-1 Channels in Abdominal Viscera Tonically Inhibits Autonomic Cold-Defense Effectors , 2007, The Journal of Neuroscience.

[5]  S. McMahon,et al.  Acid-Induced Pain and Its Modulation in Humans , 2004, The Journal of Neuroscience.

[6]  N. Carruthers,et al.  Identification and biological evaluation of 4-(3-trifluoromethylpyridin-2-yl)piperazine-1-carboxylic acid (5-trifluoromethylpyridin-2-yl)amide, a high affinity TRPV1 (VR1) vanilloid receptor antagonist. , 2005, Journal of medicinal chemistry.

[7]  A. Szallasi,et al.  The vanilloid receptor TRPV1: 10 years from channel cloning to antagonist proof-of-concept , 2007, Nature Reviews Drug Discovery.

[8]  N. Chen,et al.  Novel vanilloid receptor-1 antagonists: 2. Structure-activity relationships of 4-oxopyrimidines leading to the selection of a clinical candidate. , 2007, Journal of medicinal chemistry.

[9]  P. Anand,et al.  Increased capsaicin receptor TRPV1 nerve fibres in the inflamed human oesophagus , 2004, European journal of gastroenterology & hepatology.

[10]  C. Woolf,et al.  p38 MAPK Activation by NGF in Primary Sensory Neurons after Inflammation Increases TRPV1 Levels and Maintains Heat Hyperalgesia , 2002, Neuron.

[11]  N. Carruthers,et al.  Selective Blockade of the Capsaicin Receptor TRPV1 Attenuates Bone Cancer Pain , 2005, The Journal of Neuroscience.

[12]  A I Basbaum,et al.  Impaired nociception and pain sensation in mice lacking the capsaicin receptor. , 2000, Science.

[13]  B. Chizh,et al.  The effects of the TRPV1 antagonist SB-705498 on TRPV1 receptor-mediated activity and inflammatory hyperalgesia in humans , 2007, Pain.

[14]  R. Dionne,et al.  Comparison of nonsteroidal anti-inflammatory drugs, ibuprofen and flurbiprofen, with methylprednisolone and placebo for acute pain, swelling, and trismus. , 1990, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[15]  A. A. Romanovsky,et al.  The organum vasculosum laminae terminalis in immune-to-brain febrigenic signaling: a reappraisal of lesion experiments. , 2003, American journal of physiology. Regulatory, integrative and comparative physiology.

[16]  M. Torii,et al.  Expression and characterization of vanilloid receptor subtype 1 in human dental pulp cell cultures. , 2005, Journal of endodontics.

[17]  A. Gomtsyan,et al.  A-425619 [1-Isoquinolin-5-yl-3-(4-trifluoromethyl-benzyl)-urea], a Novel Transient Receptor Potential Type V1 Receptor Antagonist, Relieves Pathophysiological Pain Associated with Inflammation and Tissue Injury in Rats , 2005, Journal of Pharmacology and Experimental Therapeutics.

[18]  J. Treanor,et al.  Repeated Administration of Vanilloid Receptor TRPV1 Antagonists Attenuates Hyperthermia Elicited by TRPV1 Blockade , 2007, Journal of Pharmacology and Experimental Therapeutics.

[19]  P. McIntyre,et al.  The VR1 Antagonist Capsazepine Reverses Mechanical Hyperalgesia in Models of Inflammatory and Neuropathic Pain , 2003, Journal of Pharmacology and Experimental Therapeutics.

[20]  M. Caterina,et al.  Attenuated fever response in mice lacking TRPV1 , 2005, Neuroscience Letters.

[21]  S. Bingham,et al.  Vanilloid receptor-1 is essential for inflammatory thermal hyperalgesia , 2000, Nature.

[22]  John B Davis,et al.  Vanilloid receptor 1 expression in human tooth pulp in relation to caries and pain. , 2005, Journal of orofacial pain.

[23]  A. A. Romanovsky,et al.  CALL FOR PAPERS Physiology and Pharmacology of Temperature Regulation Thermoregulation: some concepts have changed. Functional architecture of the thermoregulatory system , 2007 .

[24]  D. Julius,et al.  The vanilloid receptor: a molecular gateway to the pain pathway. , 2001, Annual review of neuroscience.

[25]  P. Blumberg,et al.  Vanilloid (Capsaicin) receptors and mechanisms. , 1999, Pharmacological reviews.

[26]  Jim A. Wright,et al.  Characterization of SB-705498, a Potent and Selective Vanilloid Receptor-1 (VR1/TRPV1) Antagonist That Inhibits the Capsaicin-, Acid-, and Heat-Mediated Activation of the Receptor , 2007, Journal of Pharmacology and Experimental Therapeutics.

[27]  A. Basbaum,et al.  Molecular mechanisms of nociception , 2001, Nature.

[28]  John B Davis,et al.  Daily body temperature rhythm and heat tolerance in TRPV1 knockout and capsaicin pretreated mice , 2004, The European journal of neuroscience.

[29]  T. Hori.  Capsaicin and central control of thermoregulation. , 1984, Pharmacology & therapeutics.

[30]  J. Treanor,et al.  The Vanilloid Receptor TRPV1 Is Tonically Activated In Vivo and Involved in Body Temperature Regulation , 2007, The Journal of Neuroscience.

[31]  J. Pomonis,et al.  N-(4-Tertiarybutylphenyl)-4-(3-cholorphyridin-2-yl)tetrahydropyrazine -1(2H)-carbox-amide (BCTC), a Novel, Orally Effective Vanilloid Receptor 1 Antagonist with Analgesic Properties: II. In Vivo Characterization in Rat Models of Inflammatory and Neuropathic Pain , 2003, Journal of Pharmacology and Experimental Therapeutics.

[32]  E. Pintér,et al.  Involvement of transient receptor potential vanilloid 1 in the vascular and hyperalgesic components of joint inflammation. , 2005, Arthritis and rheumatism.